Back
Nxera Pharma Quote, Financials, Valuation and Earnings
Trump wins! Dow to 75,000? Details here
See the explosive "Document 20" details here.
Buy
52
SOLTF
Nxera Pharma
Last Price:
8.05
Seasonality Move:
20.55%
7 Day Trial
ALL ACCESS PASS
$
7
Buy these stocks BEFORE President Trump returns to the Oval Office
See details on which stocks are poised to surge.Nxera Pharma Price Quote
$8.05
0.00 (5.5%)
(Updated: November 13, 2024 at 5:24 AM ET)
Nxera Pharma Key Stats
Buy
52
Nxera Pharma (SOLTF)
is a Buy
Day range:
$8.05 - $8.05
52-week range:
$7.00 - $13.43
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3.64
P/B ratio:
1.69%
Volume:
0
Avg. volume:
220
1-year change:
-21.83%
Market cap:
$723.9M
Revenue:
$91M
EPS:
$-0.27
How Much Does Nxera Pharma Make?
-
How Much Are Nxera Pharma's Sales Annually?
SOLTF Revenues are $91M -
How Much Profit Does Nxera Pharma's Make A Year?
SOLTF net income is -$51.3M
Is Nxera Pharma Growing As A Company?
-
What Is Nxera Pharma's Growth Rate Quarterly?
Quarterly YoY revenue growth is 1.71% -
What Is Nxera Pharma's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Nxera Pharma Stock Price Performance
-
Did Nxera Pharma Stock Go Up Last Month?
Nxera Pharma share price went down by -10.73% last month -
Did SOLTF's Share Price Rise Over The Last Year?
SOLTF share price fell by -21.83% over the past 1 year
What Is Nxera Pharma 52-Week High & Low?
-
What Is Nxera Pharma’s 52-Week High Share Price?
Nxera Pharma has traded as high as $13.43 over the past 52 weeks -
What Is Nxera Pharma’s 52-Week Low Share Price?
Nxera Pharma has traded as low as $7.00 over the past 52 weeks
Nxera Pharma Price To Free Cash Flow
-
Is Nxera Pharma Stock Overvalued?
Nxera Pharma is trading at a price to free cash flow ratio of 70.97 -
Is Nxera Pharma Stock Undervalued?
Nxera Pharma EV to Free Cash Flow ratio is 81.85 -
What Is Nxera Pharma’s Price Earnings Growth Ratio?
SOLTF PEG ratio is 0.00 -
Is Nxera Pharma Trading At A Premium To Earnings?
Nxera Pharma EV to EBIT ratio is 0.00
Is It Risky To Buy Nxera Pharma?
-
How Much Debt Does Nxera Pharma Have?
Total long term debt quarterly is $0 -
How Much Cash Does Nxera Pharma Have?
Cash and short term investments quarterly total is $316.8M -
What Is Nxera Pharma’s Book Value Per Share?
Book value per share is 4.77
Is Nxera Pharma Cash Flow Positive?
-
What Is SOLTF Cash Flow From Operations?
Cash flow from operations (TTM) is $15.1M -
What Is Nxera Pharma’s Cash Flow From Financing?
Cash flow from financing (TTM) is $35.5M -
What Is Nxera Pharma’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$17.7M
Nxera Pharma Return On Invested Capital
-
Is Management Doing A Good Job?
SOLTF return on invested capital is -2.78% -
What Is Nxera Pharma Return On Assets?
ROA measures how assets are converting to revenues and is -2.4% -
What Is SOLTF Return On Equity?
ROE is a measure of profitability and is -15.46%
Nxera Pharma Earnings Date & Stock Price
-
What Is Nxera Pharma's Stock Price Today?
A single share of SOLTF can be purchased today for 8.05 -
What Is Nxera Pharma’s Stock Symbol?
Nxera Pharma trades on the otcm under the ticker symbol: SOLTF -
When Is Nxera Pharma’s Next Earnings Date?
The next quarterly earnings date for Nxera Pharma is scheduled on November 14, 2024 -
When Is SOLTF's next ex-dividend date?
Nxera Pharma's next ex-dividend date is March 27, 2015 -
How To Buy Nxera Pharma Stock?
You can buy Nxera Pharma shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Nxera Pharma Competitors
-
Who Are Nxera Pharma's Competitors?
Below is a list of companies who compete with Nxera Pharma or are related in some way:
Nxera Pharma Dividend Yield
-
What Is SOLTF Dividend Yield?
Nxera Pharma’s dividend yield currently is 0% -
What Is Nxera Pharma’s Payout Ratio?
Nxera Pharma’s payout ratio is 0% -
When Did Nxera Pharma Last Pay A Dividend?
The latest dividend pay date is November 14, 2024 -
What Is Nxera Pharma’s Dividend Per Share?
Nxera Pharma pays a dividend of $0.00 per share
Nxera Pharma Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 0% |
| Revenue: | 170.67% | 0% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 0.00 |
| Downside from Last Price: | -100% |